I spent the early part of my career as a surgeon. In that world, you are trained to identify a problem and fix it. Cut, correct, close. The framework is binary: broken or functional, diseased or clear. When I moved into cosmetic medicine, I brought that framework with me, and for years it served me reasonably well. Then longevity science arrived, and it dismantled everything I thought I knew about the skin.
Because here is what the research has now conclusively established: the skin does not simply age. It accumulates damage at the cellular level, and that accumulation is what you see in the mirror. Time is a passenger. Damage is the driver. This is the most important distinction in modern aesthetic medicine, and it is why no single cream, no single procedure, and no single lifestyle intervention will ever be enough on its own.
Let me tell you what the evidence actually says.
Act One: The Enemy Has a Name, and It Is Not Time
In 2024, an international review published in the International Journal of Dermatology outlined what we now call the twelve hallmarks of skin ageing, a framework borrowed from longevity biology and applied specifically to the dermal environment. The list includes genomic instability, telomere attrition, epigenetic alterations, mitochondrial dysfunction, and cellular senescence, among others. What is striking about this list is not its complexity. It is the fact that every single hallmark on it is, to some degree, modifiable.
Telomere attrition is perhaps the most compelling entry. Telomeres are the protective caps at the end of chromosomes, think of them as the plastic tips on a shoelace, preventing the whole structure from fraying. Every time a cell divides, those caps shorten. When they become critically short, the cell either stops dividing (entering what biologists call senescence) or dies. Research published in Biogerontology in 2025 confirmed the correlation between telomere length and visible skin ageing, proposing telomere length as a potential predictive biomarker for the skin’s biological age, as distinct from its chronological one. The same paper noted that oxidative stress, driven substantially by UV exposure and environmental pollutants, significantly accelerates telomere shortening in dermal fibroblasts.
This is where the clinical story begins, because oxidative stress is something we can address. The evidence for doing so is considerably more robust than most people, including many clinicians, realise.
Act Two: The Non-Negotiables (What No Study Has Ever Disproved)
Before discussing the interventions that require a clinic visit, a prescription, or a significant financial outlay, we must talk about the foundations. I have patients who spend extraordinary sums on regenerative procedures and then undo the benefits with inconsistent sun protection. I have patients who are faithful about their topical retinoids but sleep four hours a night and eat processed food at lunch and wonder why their skin looks exhausted.
The foundations are unglamorous. They are also non-negotiable.
Sunscreen is the most evidence-backed anti-ageing intervention in existence. In 2013, Australian researchers ran the first large-scale randomised controlled trial to test whether daily sunscreen use could meaningfully prevent the progression of photoageing in adults under 55. Nine hundred and three participants were enrolled. The conclusion was unambiguous: consistent, daily application of broad-spectrum sunscreen significantly slowed the development of photoageing compared to discretionary use. The effect was measurable in skin texture, elasticity, and pigmentation. Subjects in the daily-use group showed signs of partial reversal, going beyond baseline preservation. The recommendation that followed was equally unambiguous: broad-spectrum, SPF 30 minimum, applied generously, and reapplied. Every day. Rain or shine.
Understanding what happens without it is worth a moment. UV exposure inhibits activator protein-1 (AP-1) activity and drives collagen-degrading matrix metalloproteinases (MMPs), while simultaneously suppressing collagen synthesis. Cumulative UV exposure is responsible for approximately 80 per cent of visible facial ageing. The lines, the laxity, the pigmentation irregularity: the overwhelming majority of it is light, not time. And light is something you can partially control.
Act Three: The Molecule That Changed the Game
If sunscreen is the most evidence-backed intervention, tretinoin, prescription-strength all-trans retinoic acid, is the most mechanistically understood.
Tretinoin works through two distinct but synergistic pathways. First, when applied prior to UV exposure, it inhibits AP-1 activity, blocking the collagen-degrading MMPs at source. Second, it actively stimulates collagen synthesis by upregulating the expression of type I procollagen. It is both a shield and a repair mechanism. A systematic review and meta-analysis published in 2022, reviewing randomised controlled trials spanning decades, concluded that topical tretinoin is a safe and effective therapeutic modality for the long-term treatment of photoageing, with dramatic improvement observed across virtually all clinical signs of photodamage.
The caveat, and there always is one, is that tretinoin requires both patience and medical guidance. The initial adjustment period involves redness, peeling, and increased photosensitivity. The concentration, the formulation, the frequency, the accompanying barrier support: all of this matters enormously. A 0.025% cream used three nights a week on a patient with a compromised skin barrier is a very different proposition from 0.1% applied nightly on resilient skin. This is precisely why the intervention should be clinician-directed.
What about over-the-counter retinol? The picture is less definitive. A systematic review in the Journal of Clinical and Aesthetic Dermatology found that out of nine randomised, double-blind, vehicle-controlled trials of retinol products, four reported no statistically significant differences between retinol and vehicle, and the remaining five provided only weak evidence for a mild ameliorating effect on fine wrinkles. Retinol remains a useful, accessible ingredient. The honest assessment, though, is that the evidence hierarchy places it well below prescription tretinoin.
Act Four: What You Put In Your Mouth
The inside-out argument for skin health has graduated from alternative medicine to clinical evidence.
Collagen peptides have been the subject of multiple randomised controlled trials in recent years. A six-week, randomised, double-blind, placebo-controlled trial published in Cosmetics in 2024 evaluated low-molecular-weight collagen peptide supplementation and found significant improvements in facial wrinkle depth and skin hydration compared to placebo. The mechanistic explanation aligns with what we understand about oral bioavailability: hydrolysed collagen peptides, when ingested, are broken down into di- and tripeptides that are absorbed and distributed to dermal tissues, where they act as signalling molecules stimulating fibroblast activity and extracellular matrix production. They are telling your skin to make more of its own collagen, rather than replacing it directly.
A 2024 randomised, double-blind, placebo-controlled clinical trial published in Dermatology Research and Practice went further. Using confocal microscopy and high-resolution ultrasound to measure dermal collagen directly, by objective imaging rather than self-report or clinical impression, the researchers found a significant 44.6% decrease in collagen fragmentation following twelve weeks of daily supplementation with hydrolysed collagen and vitamin C. Forty-four point six per cent. That is a structural change measurable in tissue, not a marketing claim.
The vitamin C component matters independently. Vitamin C (L-ascorbic acid) functions as a required cofactor in collagen synthesis, supporting the hydroxylation of proline residues in procollagen to stabilise the triple-helix structure. As an antioxidant, it also neutralises free-radical species, protecting the skin from UV-induced oxidative damage. In my practice, topical and oral strategies are additive. They address different parts of the same biological problem.
Then there is niacinamide, vitamin B3, which has quietly become one of the most rigorously supported ingredients in both topical and systemic skin science. Clinical studies consistently show significant improvements in ageing signs at concentrations of 2-5% niacinamide applied topically, with documented effects including enhanced collagen synthesis, improved barrier function, reduced hyperpigmentation, and protection against oxidative stress. It is one of the few cosmetically available ingredients where the evidence base is both robust and honest.
Act Five: The Procedures Worth Having (and the Ones Still Finding Their Evidence)
I want to talk about procedures without the breathless enthusiasm that sometimes characterises clinic marketing. The science here is nuanced, and patients deserve to know that.
PRP, platelet-rich plasma, arrived with the most noise and has gradually acquired more rigorous evidence. A meta-analysis published in 2025, reviewing nine randomised controlled trials with 358 participants, found clinically meaningful improvements in skin texture and dermal density. Histologically, PRP induced a cascade of growth factors that increased dermal density, reducing wrinkles and improving skin luminosity and hydration. The significant caveat is variability in preparation protocols: platelet concentration, centrifugation method, and application technique all affect outcomes. A 2024 systematic review of 75 RCTs found a strong positive correlation between rigorous preparation protocols and PRP efficacy. The procedure is only as good as the process behind it.
Fractional non-ablative laser therapy has one of the more compelling evidence bases for procedural rejuvenation. A 2025 double-blind, split-face randomised clinical trial evaluated its capacity to improve skin barrier function, reduce wrinkles, and improve overall skin quality, finding statistically significant improvements in transepidermal water loss, elasticity, and clinical ageing signs. The split-face design matters: each patient serves as their own control, eliminating confounds. The evidence for laser therapy, used appropriately and with correct post-procedure support, is considerably stronger than for many other in-clinic interventions.
And then there is the frontier, the territory where the science is compelling and the clinical evidence is still building. NAD+ precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are among the most discussed in longevity research. A 2023 review noted promising early evidence for oral nicotinamide, including reduced risk of certain skin cancers, alongside legitimate concerns about elevated NAD+ potentially supporting cancer cell metabolism via enhanced glycolysis. These belong in the emerging adjunctive category rather than alongside established standards of care. I include them in my practice, selectively, for appropriate patients, and I present them with that caveat intact.
Exosome therapies, stem cell-based treatments, and epigenetic reprogramming strategies are being actively investigated in early-phase clinical trials. Broader clinical validation is needed to define long-term efficacy and safety profiles. They represent the most exciting horizon in regenerative dermatology, and the standard of care of five years from now is very likely being written in these trials today.
Act Six: The Epigenetic Clock and What It Means for You
Perhaps the most paradigm-shifting development in longevity science is the epigenetic clock, a tool that assesses biological age by patterns of DNA methylation across hundreds of sites in your genome rather than by how many years you have lived. Recent advancements in epigenetic clocks have provided tools to assess biological age at the molecular level, offering insights into ageing processes that frequently correspond more effectively with health outcomes than chronological age alone.
In aesthetic dermatology, this matters profoundly. Two patients of identical chronological age can have dermal biologies that differ by a decade or more. The question is never simply “what is your age?” It is “what is the biological age of your skin, and what is driving the divergence?” Procedural interventions that address only the surface, without addressing the underlying biology, are maintenance. Valuable maintenance, but maintenance nonetheless.
The twelve hallmarks of skin ageing that epigenetic science has illuminated are actionable. They respond to sun protection, to targeted topicals, to nutrition, to sleep, to stress reduction, to specific procedural interventions. The skin is a remarkably responsive organ. Respect its biology, and it will reward you in ways that filler alone cannot replicate.
What I Actually Tell My Patients
Longevity skincare is a practice, not a product category. Consistent, layered, evidence-informed, beginning with the basics and building thoughtfully from there.
It starts with SPF. Every day, rain or shine, indoors or outdoors, because glass does not block UVA.
It adds a prescription retinoid when the skin is ready for it: the version with actual evidence behind it, introduced with appropriate support and pacing, rather than the weakest over-the-counter approximation.
It considers the interior alongside the exterior: collagen peptides with vitamin C, niacinamide, antioxidants that work in the bloodstream as well as on the skin’s surface.
It adds procedural interventions when warranted and evidence-supported, chosen because the biology of that specific patient’s skin calls for them.
And it stays current. Longevity science is moving faster than any other field in medicine right now, and what sits at the frontier today may be the standard of care in five years.
The question worth asking is what is actually happening inside my skin, and what does the evidence say I should do about it?
The answer, unlike the ageing process itself, is entirely within your control.
Bibliography
Haykal, D. et al. (2025). “Unlocking Longevity in Aesthetic Dermatology: Epigenetics, Aging, and Personalized Care.” International Journal of Dermatology. https://pmc.ncbi.nlm.nih.gov/articles/PMC12605702/
Kream, E., Boen, M., & Fabi, S.G. (2025). “Skinspan: A Holistic Roadmap for Extending Skin Longevity With Evidence-Based Interventions.” PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12413659/
Li, S. et al. (2025). “Telomeres in Skin Aging.” Biogerontology. https://link.springer.com/article/10.1007/s10522-025-10228-9
Green, A.C. et al. (2013). “Sunscreen and Prevention of Skin Aging: A Randomized Trial.” Annals of Internal Medicine. https://www.acpjournals.org/doi/10.7326/0003-4819-158-11-201306040-00002
Krutmann, J. et al. (2021). “Daily Photoprotection to Prevent Photoaging.” Photodermatology, Photoimmunology & Photomedicine. https://onlinelibrary.wiley.com/doi/10.1111/phpp.12688
Alli, R. et al. (2025). “Tretinoin for Photodamaged Facial Skin: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12615114/
Mukherjee, S. et al. (2022). “Topical Tretinoin for Treating Photoaging: A Systematic Review of Randomized Controlled Trials.” PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9112391/
Rapaport, M. (2018). “Evidence for the Efficacy of Over-the-Counter Vitamin A Products in the Improvement of Facial Skin Aging.” JCAD. https://jcadonline.com/efficacy-of-over-the-counter-vitamin-a/
Carrillo-Norte, J.A. et al. (2024). “Anti-Aging Effects of Low-Molecular-Weight Collagen Peptide Supplementation on Facial Wrinkles and Skin Hydration.” Cosmetics, 11(4), 137.
Reilly, D. et al. (2024). “12-Week Oral Collagen + Vitamin C RCT.” Dermatology Research and Practice. https://onlinelibrary.wiley.com/doi/10.1155/2024/8752787
Lv, X. et al. (2025). “Meta-Analysis of PRP in Treating Skin Aging.” Aesthetic Surgery Journal Open Forum. https://academic.oup.com/asjopenforum/advance-article/doi/10.1093/asjof/ojaf150/8322866
Phoebe, K. et al. (2024). “Use of Platelet-Rich Plasma for Skin Rejuvenation.” Skin Research and Technology. https://onlinelibrary.wiley.com/doi/10.1111/srt.13714
Zhang, X. et al. (2025). “Nonablative Fractional Laser + Multibeneficial Serum: Blinded RCT.” PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873370/
Lim, S. et al. (2026). “Integrative Dermatology for Longevity.” Dermatology and Therapy. https://link.springer.com/article/10.1007/s13555-026-01732-y
Wyles, C. et al. (2025). “Longevity Cosmeceuticals: Scientific Framework.” Frontiers in Aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC12137348/
Jafferany, M. et al. (2025). “Advances in Longevity: Regenerative Medicine and Cosmetic Dermatology.” PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12268380/
